(UroToday.com) In this presentation, Dr. Richard Cathomas presented results from SAKK 08/16, a randomized double-blind placebo-controlled phase II trial of darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane. This study sought to assess whether an immediate switch to darolutamide after disease stabilization with taxane chemotherapy for patients with mCRPC and prior NHA treatment might improve radiographic progression-free survival (rPFS).